Pulmonary Hypertension Complicating Fibrosing Mediastinitis

Andrei Seferian, MD, Alexandru Steriade, MD, Xavier Jaïs, MD, Olivier Planché, MD, PhD, Laurent Savale, MD, PhD, Florence Parent, MD, David Amar, MD, Roland Jovan, MD, Elie Fadel, MD, PhD, Olivier Sitbon, MD, PhD, Gérald Simonneau, MD, Marc Humbert, MD, PhD, and David Montani, MD, PhD

Abstract: Fibrosing mediastinitis is caused by a proliferation of fibrous tissue in the mediastinum with encasement of mediastinal viscera and compression of mediastinal bronchovascular structures. Pulmonary hypertension (PH) is a severe complication of fibrosing mediastinitis caused by extrinsic compression of the pulmonary arteries and/or veins.

We have conducted a retrospective observational study reviewing clinical, functional, hemodynamic, radiographic characteristics, and outcome of 27 consecutive cases of PH associated with fibrosing mediastinitis diagnosed between 2003 and 2014 at the French Referral Centre for PH.

Fourteen men and 13 women with a median age of 60 years (range 18–84) had PH confirmed on right heart catheterization. The causes of fibrosing mediastinitis were sarcoidosis (n = 13), tuberculosis-infection confirmed or suspected (n = 9), mediastinal irradiation (n = 2), and idiopathic (n = 3). Sixteen patients (59%) were in NYHA functional class III and IV. Right heart catheterization confirmed moderate to severe PH with a median mean pulmonary artery pressure of 42 mm Hg (range 27–90) and a median cardiac index of 2.8 L/min/m² (range 1.6–4.3). Precapillary PH was found in 22 patients, postcapillary PH in 2, and combined precapillary and precapillary PH in 3. Severe extrinsic compression of pulmonary arteries (>60% reduction in diameter) was evidenced in 2, 8, and 12 patients at the main, lobar, or segmental levels, respectively. Fourteen patients had at least one severe pulmonary venous compression with associated pleural effusion in 6 of them. PAH therapy was initiated in 7 patients and corticosteroid therapy (0.5–1 mg/kg/day) was initiated in 3 patients with sarcoidosis, with 9 other being already on low-dose corticosteroids. At 1-year follow-up, 3 patients had died and among the 21 patients evaluated, 3 deteriorated, 14 were stable, and only 4 patients with sarcoidosis improved (4 receiving corticosteroids and 1 receiving corticosteroids and PAH therapy). Survival was 88%, 73%, and 56% at 1, 3, and 5 years, respectively.

We found no clear clinical improvement with the use of specific PAH therapy. Corticosteroid therapy may be associated with clinical improvement, in some patients with fibrosing mediastinitis due to sarcoidosis. Although never performed for this indication, lung transplantation may be proposed in eligible patients with severe PH and fibrosing mediastinitis.

(Introductory) Pulmonary hypertension (PH) is a progressive, severe hemodynamic disorder, which can be potentially fatal if left untreated. It is defined by an elevation of the pulmonary artery pressure above 25 mm Hg that leads to right ventricular failure. Assessment by right heart catheterization (RHC) is mandatory for diagnosis and multiple tests are used to classify PH in 1 of the 5 clinical groups.1,2 Group 1 PH corresponds to pulmonary arterial hypertension, PH due to idiopathic, heritable, induced by drugs or toxins, and associated with connective tissue disease, HIV infection, congenital heart disease, or portal hypertension.2 A variety of hematologic, systemic, or metabolic disorders associated with PH by unclear and/or multifactorial mechanisms form group 5 of the classification. Pulmonary hypertension complicating fibrosing mediastinitis has been classified in group 5.3

Fibrosing mediastinitis is a rare, benign, but potentially lethal disorder caused by a proliferation of fibrous tissue in the mediastinum with encasement of the mediastinal viscera and extrinsic compression of mediastinal bronchovascular structures, which leads to a progressive, insidious disease with

**Abbreviations:** 6MWD = 6-minute walking distance, CO = cardiac output, CTEPH = chronic thromboembolic pulmonary hypertension, DLCO = diffusion capacity for carbon monoxide, ERA = endothelin receptor antagonist, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, HRCT = high-resolution computer tomography, mPAP = mean pulmonary arterial pressure, NYHA = New York Heart Association, PaCO2 = partial pressure of arterial carbon dioxide, PAH = pulmonary arterial hypertension, PaO2 = partial pressure of arterial oxygen, PDE5-I = phosphodiesterase 5 inhibitor, PH = pulmonary hypertension, PVR = pulmonary vascular resistance, RAP = right atrial pressure, RHC = right heart catheterization, TLC = total lung capacity, V/Q lung scan = ventilation perfusion lung scan, WU = wood units.
variable natural history. The most important series of cases describe American patients with fibrosing mediastinitis complicating histoplasmosis. Reports also point out to a possible association with other fungal infections including aspergillosis, blastomycosis, mucormycosis, cryptococcosis, or infection with Wuchereria bancrofti. Fibrosing mediastinitis has also been reported in the context of autoimmune disease (rheumatoid arthritis and systemic lupus erythematosus), Behçet disease, mediastinal radiation, and therapy with methysergide. Lastly, an idiopathic, nongranulomatous form has been described. Clinical presentation depends largely upon which structures of the mediastinum are affected, with cough, chest pain, and dyspnea being the main symptoms. Typical complications include supraventricular tachycardia syndrome, large airways compression which can lead to post obstructive pneumonia or atelectasis, bronchial erosion by calcific lymph nodes, oesophageal compression or pulmonary artery, and/or vein compression. Patients with compression of pulmonary vessels can have hemothysis due to bronchial artery hypertrophy, which is frequently observed in fibrosing mediastinitis. Imaging studies and suggestive clinical context are usually sufficient to confirm the diagnosis. Diagnosis may be challenging in the context of PH because pulmonary arterial compression PH and right heart failure are considered to be an important cause of morbidity and mortality in fibrosing mediastinitis.

In this study, we report the experience of the French Referral Centre for Pulmonary Hypertension (Université Paris Sud, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin Bicêtre, France) in the diagnosis, management and outcomes of consecutive patients with PH complicating fibrosing mediastinitis.

**METHODS**

**Subjects**

We have conducted a retrospective observational study reviewing all incident cases from the French PH Registry of confirmed precapillary PH among patients in whom the cause was fibrosing mediastinitis. This Registry was established in accordance with French bioethics laws (Commission Nationale de l’Informatique et des Libertés), and all patients gave their informed consent. Diagnosis of PH defined as mean pulmonary arterial pressure (mPAP) ≥ 25 mm Hg was confirmed in all patients by RHC. Routine evaluation at baseline included medical history, physical examination, echocardiography, contrast-enhanced high-resolution computed tomography (HRCT) of the chest, ventilation/perfusion (V/Q) lung scan, pulmonary angiography, abdominal ultrasound, autoimmunity screening, and HIV serology. For the present report, all data were reviewed and the diagnosis of PH complicating fibrosing mediastinitis was confirmed after a multidisciplinary meeting including senior pulmonologists (AS, XJ, LS, FP, OS, GS, MH, DM), radiologists (OP), and thoracic surgeons (EF). The cause of fibrosing mediastinitis was determined based on patient’s medical history. Confirmed tuberculosis as the cause of fibrosing mediastinitis was defined as a definitive history of positive culture for Mycobacterium tuberculosis or history of treatment for tuberculosis. Tuberculosis was considered as suspected in patients with compatible clinical history of tuberculosis, originating from endemic countries and compatible parenchymal post tuberculosis sequelae on HRCT of the chest. A diagnosis of sarcoidosis required histological evidence of noncaseating granulomas in lymph nodes or bronchial biopsies.

**Hemodynamic Assessment**

Right atrial pressure (RAP), systolic, diastolic and mean PA, pulmonary artery wedge pressure (PAWP), and mixed venous saturation (SvO2) were measured during RHC. Cardiac output (CO) was measured by the standard thermodilution technique. The cardiac index was calculated as the CO/body surface area, expressed in L/min/m². Pulmonary vascular resistance (PVR) was calculated as (mPAP-PAWP)/CO, expressed in Wood units (WU). Acute vasodilator testing was performed during RHC with inhaled nitric oxide, as previously described. Precapillary PH was retained if PAWP was ≤ 15 mm Hg, and postcapillary PH was retained if PAWP was > 15 mm Hg. In the presence of elevated PAWP, a gradient between diastolic PA and the PAWP ≥ 7 mm Hg was used to establish a diagnosis of combined postcapillary PH with a precapillary component.

**Clinical and Functional Assessment**

Dyspnea was assessed at PH diagnosis by New York Heart Association (NYHA) functional class. A nonencouraged 6-min walk test according to recommendations was performed. Arterial blood gases and pulmonary function tests were recorded, including partial pressure of arterial oxygen (PaO2) and partial pressure of arterial carbon dioxide (PaCO2), the forced expiratory volume in 1 second (FEV1), the forced vital capacity (FVC), the total lung capacity (TLC), and diffusing capacity for carbon monoxide (DLCO). An obstructive and restrictive pattern was defined as a FEV1/FVC < 0.7 and TLC < 80% predicted respectively, whereas a mixed pattern was a combination of the both.

**Radiologic Findings**

All HRCT of the chest, V/Q lung scans and pulmonary angiography, were reviewed by experienced PH specialists and radiologists (AS, OP, DM). Arterial, venous, or bronchial compressions were evaluated by measuring the reduction in diameter of their lumen in the axial plane. For bronchi and pulmonary arteries, compressions were analyzed at the main pulmonary, lobar, and segmental levels. For pulmonary veins, compressions were evaluated at the level of the main superior and inferior left and right pulmonary veins. The threshold of a reduction of 60% in diameter of pulmonary arteries and bronchi with respect to upstream or downstream diameter was chosen to define severe stenoses. When a lobar artery (or bronchus) appeared severely stenosed over all its length, the downstream diameter used to confirm this severe stenosis was estimated from the distal normal diameter of its segmental branches. If no distal normal diameter could be found because all these branches were also severely affected over all their length or occluded, the lobar artery or bronchus was considered severely stenosed. For pulmonary veins, severe stenoses were defined as a reduction in diameter of >60% when compared to the normal diameter of the vein upstream or downstream of the stenosis. When no normal diameter could be found, stenoses were estimated as an average of the stenoses of its immediate tributary veins. Other parameters on HRCT were evaluated including the lung parenchyma, the presence of pleural or pericardial effusion, the oesophagus, the superior vena cava, and the retroperitoneal space.
Statistical Analysis
All results are presented as median (range). Information on survival was available for all patients on December 31st 2014. Survival analysis was performed by using the Kaplan–Meier survival curve by using the GraphPad Prism 6 software (La Jolla, CA).

RESULTS
Subjects
Between 2003 and 2014, 31 patients with fibrosing mediastinitis and possible PH were evaluated at the French PH Referral Central. Of note, 4 patients (1 silicosis and 3 tuberculosis) had no PH, but mild elevation in mPAP ranging between 20 and 24 mm Hg and therefore were not included in our analysis. Thus, PH was confirmed by RHC in 27 patients. Anthropometric data, clinical, functional, and hemodynamic parameters of patients with PH complicating fibrosing mediastinitis are summarized in Tables 1 to 3. There were a total of 14 men and 13 women with a median of age of 60 years (range 18–84). Fifteen patients were Caucasians and 12 were Africans. The mean delay between the onset of symptoms and PH diagnosis was almost 3 years. Thirteen patients developed fibrosing mediastinitis in the context of sarcoidosis, 7 of them having stage 4 disease. In 9 patients, history of tuberculosis was suspected (n = 6) or confirmed (n = 3). Irradiation of the mediastinum was incriminated in 2 patients. One patient received radiotherapy of the mediastinum 30 years before for Hodgkin lymphoma, whereas the second one was irradiated for a locally advanced breast carcinoma 15 years prior to PH diagnosis. For the remaining 3 patients, no cause of fibrosing mediastinitis was found and fibrosing mediastinitis was considered idiopathic.

Clinical and Functional Characteristics
Sixteen patients (59%) had severe exercise limitation and were in NYHA functional classes III and IV. The median 6-min walking distance (6MWD) was 338 m (range 188–577). No patient had clinical superior ven a cava syndrome and 6 patients had history of mild hemoptyis. Pulmonary function tests confirmed an obstructive pattern in 15 patients, a restrictive pattern in 3 patients, a mixed pattern in 3 patients, and only 6 patients had normal lung volumes and flows. The median TLC was 83% of theoretical values (range 50–108), the median FVC was 70% (range 35–98). Diffusion capacity for carbon monoxide was reduced at 95). Diffusion capacity for carbon monoxide was reduced at (range 35–98), whereas the median FEV1 was 55% (range 28–95). FEV1/FVC was 65% of theoretical values (range 50–108), the median PaCO2 was 5.0 (range 4–6.6).

| TABLE 1. Etiologies of Fibrosing Mediastinitis |
|-----------------------------------------------|
| PH Associated with Fibrosing Mediastinitis, n = 27 |
| Sarcoïdosis (stage 4) | 13 (7) |
| Tuberculosis | 9 |
| – confirmed | 3 |
| – possible | 6 |
| Mediastinal irradiation | 2 |
| Idiopathic | 3 |

| TABLE 2. Characteristics of Patients With Pulmonary Hypertension Complicating Fibrosing Mediastinitis |
|-----------------------------------------------|
| Pulmonary Hypertension Complicating Fibrosing Mediastinitis, n = 27 |
| Age at time of diagnosis, y | 60 (18–84) |
| Sex ratio, M/F | 14/13 |
| NYHA functional class | I/II 11 |
| III | 12 |
| IV | 4 |
| 6MWD, meters | 338 (188–570) |
| Pulmonary function tests | –FEV1, % exp 55 (28–95) |
| –FVC, % exp 70 (35–98) |
| –FEV1/FVC 65 (39–82) |
| –TLC, % exp 83 (50–108) |
| –DLCO, % exp 58 (18–98) |
| –PaO2, kPa 9.2 (6.8–14) |
| –PaCO2, kPa 5.0 (4–6.6) |

Data are presented as median (range). % exp = percent of predicted value, 6MWD = 6-minute walk distance, DLCO = diffusion capacity of carbon monoxide, FEV1 = forced expiratory value in 1 second, FVC = forced vital capacity, NYHA FC = New York Heart Association functional class, PaCO2 = partial pressure of carbon dioxide, PaO2 = partial pressure of oxygen, TLC = total lung capacity.

| TABLE 3. Hemodynamics of Patients With Pulmonary Hypertension Complicating Fibrosing Mediastinitis |
|-----------------------------------------------|
| Pulmonary Hypertension Complicating Fibrosing Mediastinitis, n = 27 |
| mPAP, mm Hg | 42 (27–90) |
| RAP, mm Hg | 4 (1–16) |
| PAwP, mm Hg | 8 (2–26) |
| CO, L/min | 4.7 (3.1–7.7) |
| CI, L/min/m² | 2.8 (1.6–4.3) |
| PVR, Wood units | 6.2 (1.7–20) |
| SvO2,% | 64 (56–81) |

Data are presented as median (range). CI = cardiac index, CO = cardiac output, mPAP = mean pulmonary artery pressure, PAwP = pulmonary artery wedge pressure, PVR = pulmonary vascular resistance, RAP = right atrial pressure, SvO2 = mixed venous oxygen saturation.
Radiological findings of patients with PH complicating fibrosing mediastinitis are presented in Table 4. Figure 1 illustrates a typical case with pulmonary arterial, bronchial, and pulmonary venous compression. Calcified lymph nodes of >1 cm were found in 15 of the 27 patients (55%). At the pulmonary arterial level, fibrosing mediastinitis severely compressed (>60% of the arterial lumen) main pulmonary, lobar, and segmental arteries in 2, 8, and 12 patients, respectively. Compression of at least 1 pulmonary vein (>60% of the venous lumen) was found in 14 of the 27 patients. Severe bronchial compression (>60% of the bronchial lumen) was found at the lobar and segmental levels in 8 and 12 patients, respectively. Atelectasis was present in 10 patients (37%), all of them having bronchial compression at the lobar and/or segmental levels. Pulmonary parenchymal abnormalities including ground glass opacities, septal lines, peribronchovascular thickening, and micronodules were observed in 18 (66%), 6 (22%), 11 (40%), and 5 (19%) patients, respectively. Fourteen patients had associated pulmonary fibrosis and 11 patients (40%) had severe pulmonary fibrosis (2 patients with previous history of radiotherapy, 7 with stage 4 sarcoidosis, and 2 with a history of tuberculosis). High-resolution computer tomography of the chest showed pleural effusion in 5 patients (19%), 3 of them having a severe venous compression in at least 1 pulmonary vein. Pericardial effusion was found in 4 patients (15%), 3 with sarcoidosis, and 1 with a suspected history of tuberculosis. Retroperitoneal fibrosis was not observed in any of the 27 patients. A compression of the superior vena cava defined by a reduction of at least 60% of the superior vena cava lumen was found in 2 patients. Hypertrophic systemic bronchial arteries were identified in 6 of the 27 patients.

V/Q lung scans were performed in 22 of the 27 patients, showing ventilation defects in 14 (63%), and segmental perfusion defects in 21 (95%). Fifteen patients (68%) had unmatched perfusion defects. Six patients underwent pulmonary angiography to exclude chronic thromboembolic pulmonary hypertension (CTEPH) and confirm extrinsic compression or encasement of pulmonary arteries.

### Initial Management

After diagnosis of PH complicating fibrosing mediastinitis, off-label PAH therapy was initiated in 6 patients with precapillary PH (4 with sarcoidosis, 1 with suspected tuberculosis, and 1 considered as idiopathic). There were no predefined criteria for the use of PAH therapies, as each case was evaluated by experts at the time of PH diagnosis and therapy was conservatively initiated on a case per case basis. Treated patients received oral therapy with either endothelin receptor antagonists (ERA), phosphodiesterase 5 inhibitors (PDE5-i) or both. Corticosteroids were started at the dose of 0.5 to 1 mg/kg in 3 patients with fibrosing mediastinitis secondary to sarcoidosis. Nine other patients with fibrosing mediastinitis and sarcoidosis were already on corticosteroids at a mean dose of 20 mg/day (range 5–30 mg/d) at time of PH diagnosis. Concomitant use of PAH therapies and corticosteroids was recorded in 4 patients all of them with sarcoidosis. Anticoagulants were prescribed to 18 (67%) patients in order to reduce the risk of thrombosis, and 14 (52%) patients received diuretics to prevent fluid retention.

### Follow-up and Survival

Median follow-up was 19 months (range 1–235). The survival analysis for all the patients is presented in Figure 2 showing 88%, 73%, and 56% survival rates at 1, 3, and 5 years respectively. A total of 8 patients died on follow-up, 5 with sarcoidosis, 1 with confirmed tuberculosis, and 2 with history of radiotherapy. Six patients died due to terminal right heart failure, whereas the rest of them due to acute respiratory failure complicating chronic respiratory failure. As not all the patients underwent hemodynamic assessment on follow-up, we used NYHA functional class as the main criteria to evaluate evolution of our patients. At 1 year of follow-up, 3 patients were dead and 21 patients were evaluated, showing clinical improvement in 4 patients, stability in 14 patients, and deterioration in 3 (Fig. 3). All the 4 patients with improved NYHA functional class had precapillary PH and sarcoidosis (2 with stage 4 disease and 2 with mild interstitial lung disease), all of them being on corticosteroids (3 on stable low dose and 1 initiated at 1 mg/kg/day 1 year before) and 1 also on PAH therapy. Right heart catheterization was performed in 3 of them confirming hemodynamic improvements with a reduction in PVR of 10%, 11%,
and 75%, respectively. At time of diagnosis 1 of these patients with sarcoidosis underwent whole body positron emission tomography, which showed extensive metabolism of the mediastinum. This patient improved dramatically with corticosteroid therapy at a dose of 1 mg/kg (case presented in Figure 4).

On long-term follow-up, none of the other patients improved NYHA functional class and 5 other patients died, whereas a total of 7 patients deteriorated at their last visit after more than 1 year.

**DISCUSSION**

Fibrosing mediastinitis is an uncommon disorder characterized by inflammation and progressive fibrosis within the mediastinum. Pathophysiological mechanisms leading to fibrosing mediastinitis are largely unknown. The fibrotic process is thought to be a sequel of active granulomatous diseases, with immunogenic material causing an intense fibrotic reaction. The largest series of fibrosing mediastinitis were reported in the context of histoplasmosis. In this particular

![FIGURE 1. Contrast-enhanced high-resolution computed tomography of the chest of a patient with pulmonary hypertension complicating fibrosing mediastinitis. Panels A and B: Cross-sectional and coronal views showing extrinsic bilateral main pulmonary arteries compression by fibrosing mediastinitis, Panel C: Coronal view showing extrinsic venous compression, Panel D: Coronal view showing bilateral bronchial compression.](image)

![FIGURE 2. Overall 5-year survival of 27 patients with pulmonary hypertension complicating fibrosing mediastinitis.](image)

![FIGURE 3. Comparison of New York Heart Association (NYHA) functional class at baseline and at 12 months (n = 25).](image)
older than the previously reported age in the largest American posthistoplasmosis cohort (median of 42 years). This difference may be explained at least in part by the differences in the causes of fibrosing mediastinitis.

The majority of our patients had severe clinical and functional impairment with 59% of patients in NYHA functional class III or IV at PH diagnosis. The main reported symptom was exertional dyspnea and all patients were addressed to our PH clinic for the investigation of an increased estimated systolic pulmonary arterial pressure on echocardiography. For the vast majority of patients, fibrosing mediastinitis was not suggested at time of referral and the main suspected diagnosis was CTEPH because of mismatched segmental perfusion defects on V/Q lung scan. Diagnosis of fibrosing mediastinitis was based on HRCT of the chest and pulmonary angiography for the most difficult cases after adjudication by a panel of PH experts including pulmonologists, radiologists, and thoracic surgeons. Figure 5 shows a typical case of PH complicating fibrosing mediastinitis that could masquerade as CTEPH.

Right heart catheterization showed great disparities, some patients having mild PH and others severe hemodynamic impairment. Most of the patients (22/27) had pure precapillary PH but postcapillary PH was present in 5 patients (isolated in 2 and associated to precapillary PH in 3 patients). Severe pulmonary venous compression probably explained this postcapillary component in these 5 patients without comorbid cardiac disease. Pulmonary fibrosis was found in 14 of the 27 patients, 11 of them having a severe form. Most of these patients had either sarcoidosis with an important interstitial pulmonary disease or extensive sequelae of tuberculosis. Thus, we could not exclude that part of the increased PVR may be secondary to parenchymal involvement. It is worth mentioning that 3 of the 4 patients with pericardial effusions died on follow-up, which underlines that this specific PH severity factor may also play a prognostic role in some Group 5 PH patients. Pleural effusions were found in patients with at least 2 pulmonary veins severely occluded. Unlike previously reported symptoms in fibrosing mediastinitis associated with histoplasmosis, only 2 of our patients had radiological compression compatible with a superior vena cava syndrome but without any clinical manifestation. This difference in clinical presentation may be explained by the preferential localization of fibrosing mediastinitis, predominating in superior mediastinum for histoplasmosis and in medium mediastinum for patients who developed pulmonary vascular compression.

As the patients were evaluated over a large period of time (from 2003 to 2014) our initial management of PH and fibrosing mediastinitis was influenced by the available tools and our growing expertise. As part of the initial management, corticosteroids were newly introduced in only 3 patients, whereas 9 other patients were already on corticosteroids. They were used in patients with fibrosing mediastinitis associated with pulmonary sarcoidosis. Positron-emission tomography (PET-scanning) was performed at time of diagnosis in 3 patients with sarcoidosis showing activity of the disease and incited us to start corticosteroids in these patients. The initial result of the PET scanning was not a good predictor for response to corticosteroids as the clinical condition only improved in 1 of these patients. Such a resistance to corticosteroid therapy was also described by Peikert et al., in their cohort of fibrosing mediastinitis due to histoplasmosis and may be explained by the advanced fibrotic lesions in which inflammation may have a lesser role. Taking into account these facts, the place of corticosteroid therapy in context, it has been demonstrated that tissues of fibrosing mediastinitis were characterized by an accumulation of CD20-positive B lymphocytes. An association between fibrosing mediastinitis and MHC class I antigen presentation molecules HLA-A2 has been reported, which supports the involvement of host-specific immune factors. The end of these processes is the development of nonspecific respiratory or extra-respiratory symptoms due to compression of the mediastinal bronchial and/or vascular structures.

PH provoked by the extrinsic compression of the pulmonary arteries is considered as a rare but severe complication of fibrosing mediastinitis. To our knowledge we report in the present study the largest series of patients with fibrosing mediastinitis complicated by PH, all confirmed by RHC. Unlike previous American series, none of our patients had history of Histoplasma capsulatum infection. By contrast, sarcoidosis and tuberculosis are relatively common causes of thoracic granulomatous disease in Africans and Europeans and were the leading causes of fibrosing mediastinitis in our series, confirming previous findings by Mole et al. Thoracic radiotherapy was found in a couple of cases, whereas only 3 patients had no obvious etiologies and were considered to have idiopathic fibrosing mediastinitis. The age of diagnosis of PH complicating fibrosing mediastinitis was 60 years in our cohort.
the management of patients with PH complicating fibrosing mediastinitis is still unclear and further studies are needed to better define their indications.

Off-label use of PAH therapy was based on hemodynamic severity. One treated patient died on follow-up, whereas the rest of them remained either stable or improved their NYHA functional class. However, we cannot issue formal recommendations on PAH drug use taking into account the heterogeneity of pulmonary arterial, venous, or lung parenchymal involvement. Use of PAH therapy must be carefully evaluated in these patients because these drugs may induce pulmonary edema in the case of pulmonary venous involvement or deteriorate arterial oxygen saturation in the case of severe parenchymal involvement. As the main mechanism of PH in these patients was compression of main pulmonary arteries, the rationale for using PAH therapies is weak in PH complicating mediastinal fibrosis.

Due to the extrinsic compression on pulmonary arteries and veins at different levels and the abnormalities of blood flow, one can suggest that there is an increased risk of thrombosis in these patients, which may incite the prescription of anticoagulants. However, hypertrophy of the bronchial arteries was found in 6 patients, 3 of them having history of mild hemoptysis. Therefore the benefit/risk ratio must be taken into account before initiating anticoagulation.

FIGURE 5. V/Q lung scan, contrast-enhanced high-resolution computed tomography and pulmonary angiography in a patient with pulmonary hypertension complicating fibrosing mediastinitis masquerading as chronic thromboembolic pulmonary hypertension. Panel A: V/Q lung scan showing multiple segmental perfusion defects in contrast with normal ventilation. Panels B: selective right pulmonary angiogram showing filiform right pulmonary arteries. Panels C and D: cross-sectional and coronal views of contrast-enhanced high-resolution computed tomography showing extrinsic pulmonary arterial compression by fibrosing mediastinitis. Post = posterior view on V/Q lung scan; RPO = right posterior oblic view on V/Q lung scan.

In the literature, there are few reports of using nonsurgical or surgical procedures to resolve superior vena cava, bronchial and pulmonary arterial or venous compressions.\textsuperscript{9,24,34,35} Peikert et al reported that balloon pulmonary artery angioplasty/stent, balloon pulmonary vein angioplasty, or bypass surgery for the superior vena cava syndrome were sometimes feasible in fibrosing mediastinitis.\textsuperscript{9} However, hemodynamic effects and long-term efficacy of these procedures are currently unknown. Up-to-date in literature there are no reports on lung transplantation in patients with fibrosing mediastinitis. In theory such an attitude may be indicated in the most severe forms, but the surgical procedure can be very complicated due to mediastinal adherences. It is important to mention that 1 of the patients with fibrosing mediastinitis associated with tuberculosis had a clinical superior vena cava syndrome that required a surgical by-pass between the brachiocephalic vein and the right atrium. Four years later, the patient started complaining of exertional dyspnea with a severe proximal bilateral pulmonary artery stenosis. A RHC was performed and found no PH, but a mild
elevation of the mPAP of 24 mm Hg. Despite the absence of PH, but taking into account the clinical and radiological aspect we decided to perform 2 additional by-passes between the main pulmonary artery and the distal part of the right and left pulmonary arteries. The patient is still alive 13 years after the surgery and is asymptomatic with a normal echocardiography advocating maybe for a preventive surgery before the development of PH.

Rituximab has been proposed in 3 patients with fibrosing mediastinitis associated with histoplasmosis.9,36 By targeting surface antigen CD20, rituximab may eliminate B lymphocytes which infiltrate sheets or follicular structures associated with areas of fibrosis.9,36 It helped reduce lesion size and metabolic activity in the mediastinum in all 3 patients.36 However, further studies are needed to evaluate the potential impact of this therapy in these patients.

When compared with the only analysis performed up to date by Peikert et al, there is a clear difference in survival in our cohort.9 Having PH complicating fibrosing mediastinitis is associated with a poor prognosis (70% of our patients were alive 3 years after PH diagnosis as compared to >95% in the American cohort of histoplasmosis without PH). This difference could be explained by a more severe hemodynamic compromise at diagnosis unresponsive to medical therapy and also by the frequent severe parenchymal involvement observed in our patients with a history of sarcoidosis or tuberculosis.

Our study has several limitations. First, it is limited to the experience of a single national referral centre over a long period of time. Gradually, novel specific oral PAH therapies have become available and their use in clinical practice evolved in parallel. Another limitation is that the diagnosis of fibrosing mediastinitis was not confirmed histologically because mediastinoscopy or endoscopic bronchial ultrasound fiberoptic bronchoscopy with biopsies were considered as high-risk procedures in most PH patients. In almost all cases, use of corticosteroids was not incited by positive PET-scanning, as the availability of this investigation has also evolved recently. Last, some patients had no hemodynamic assessment on follow-up, and we cannot therefore discuss the progression of PH.

In conclusion, our series indicates that PH complicating fibrosing mediastinitis is a severe and complex condition with an important clinical and survival impact. Correct diagnosis of this association might be challenging but HRCT of the chest is helpful to characterize pulmonary arterial, venous, and bronchial compression and rule out CTEPH. The causes of fibrosing mediastinitis in France are different from the American cohorts, as sarcoidosis, tuberculosis, and mediastinal irradiation represent the vast majority of recognized cases. There was no clear clinical improvement with the use of PAH therapy and corticosteroids may be rarely associated with clinical improvement, in particular in active sarcoidosis. Further studies are needed to evaluate the impact of innovative therapies targeting the fibrotic process of the fibrosing mediastinitis and pulmonary angioplasty to tackle the consequences of arterial stenosis. Last, lung transplantation may be proposed in eligible patients with severe PH and fibrosing mediastinitis.

REFERENCES
1. Hoeper MM, Bogard DJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D42–50.
2. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34–41.
3. Galí N, Humbert M, Vachiery JL, et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPc), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2015;36:eiv317.
4. McNeely MF, Chung JH, Bhalla S, et al. Imaging of granulomatous fibrosing mediastinitis. Am J Roentgenol. 2012;199:319–327.
5. Sherrick AD, Brown LR, Harms GF, et al. The radiographic findings of fibrosing mediastinitis. Chest. 1994;106:484–489.
6. Loyd JE, Tillman BF, Atkinson JB, et al. Mediastinal fibrosis complicating histoplasmosis. Medicine. 1988;67:295–310.
7. Hasegawa K, Ohno S, Takada M, et al. Sarcoidosis complicated with major pulmonary artery obstruction and stenosis. Intern Med. 2012;51:2775–2780.
8. Cardenal F, Pallares C, Vera L, et al. Superior vena cava syndrome due to tuberculous mediastinal fibrosis. Report of two cases (author’s transl). Medicina Clinica. 1979;73:103–108.
9. Peikert T, Colby TV, Midthun DE, et al. Fibrosing mediastinitis: clinical presentation, therapeutic outcomes, and adaptive immune response. Medicine. 2011;90:412–423.
10. Wheat LJ, Slama TG, Eitzen HE, et al. A large urban outbreak of histoplasmosis: clinical features. Ann Intern Med. 1981;94:331–337.
11. Morrone N, Gama e Silva Volpe VL, Dourado AM, et al. Bilateral pleural effusion due to mediastinal fibrosis induced by radiotherapy. Chest. 1993;104:1276–1278.
12. Gilbert HM, Hartman BJ. Short report: a case of fibrosing mediastinitis caused by Wuchereria bancrofti. Am J Trop Med Hyg. 1996;54:596–599.
13. Puri S, Factor SM, Farmer P. Sclerosing mediastinitis. presumed to be due to primary aspergillosis. New York State J Med. 1977;77: 1774–1777.
14. Othmani S, Bahri M, Louzir B, et al. [Mediastinal fibrosis combined with Behcet’s disease. Three case reports]. La Revue de medecine interne. 2000;21:330–336.
15. Male TM, Glover J, Sheppard MN. Sclerosing mediastinitis: a report on 18 cases. Thorax. 1995;50:280–283.
16. Dechambre S, Dorjee J, Fastrez J, et al. Bronchial stenosis and sclerosing mediastinitis: an uncommon complication of external thoracic radiotherapy. Eur Resp J. 1998;11:1188–1190.
17. Graham JR, Suby HI, LeCompte PR, et al. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med. 1966;274:359–368.
18. Worrell JA, Donnelly EF, Martin JB, et al. Computed tomography and the idiopathic form of proliferative fibrosing mediastinitis. J Thoracic Imaging. 2007;22:235–240.
19. Takahashi K, Horio H, Murakami S, et al. [Fibrosing mediastinitis diagnosed by thoracoscopic biopsy]. Kyobu geka. 1993;46:1774–1777.
20. Shackle HJS, Vane JW, Bhatia H, et al. Sclerosing mediastinitis: an uncommon complication of external thoracic radiotherapy. Eur Resp J. 1998;11:1188–1190.
21. Graham JR, Suby HI, LeCompte PR, et al. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med. 1966;274:359–368.
22. Novella Sanchez L, Sanz Herrero F, Berraondo Fraile J, et al. Mediastinal fibrosis and superior vena cava syndrome. Archivos de bronconeumologia. 2013;49:340–342.
23. Espinosa RE, Edwards WD 3rd, Rosenow EC, et al. Idiopathic pulmonary hilar fibrosis: an unusual cause of pulmonary hypertension. Mayo Clinic Proc. 1993;68:778–782.

24. Berry DF, Bucigrossi D, Peabody J, et al. Pulmonary vascular occlusion and fibrosing mediastinitis. Chest. 1986;89:296–301.

25. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105–3111.

26. Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J. 2010;31:1898–1907.

27. Vachiery JL, Adir Y, Barbera JA, et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol. 2013;62:D100–108.

28. ATS statement: guidelines for the six-minute walk test. Am J Resp Crit Care Med. 2002;166:111–117.

29. Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Resp J. 2014;44:1428–1446.

30. Davis AM, Pierson RN, Loyd JE. Mediastinal fibrosis. Semin Respir Infect. 2001;16:119–130.

31. Goodwin RA, Nickell JA, Des Prez RM. Mediastinal fibrosis complicating healed primary histoplasmosis and tuberculosis. Medicine. 1972;51:227–246.

32. Peebles RS, Carpenter CT, Dupont WD, et al. Mediastinal fibrosis is associated with human leukocyte antigen-A2. Chest. 2000;117:482–485.

33. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153–2165.

34. Doyle TP, Loyd JE, Robbins IM. Percutaneous pulmonary artery and vein stenting: a novel treatment for mediastinal fibrosis. Am J Resp Crit Care Med. 2001;164:657–660.

35. Guerrero A, Hoffer EK, Hudson L, et al. Treatment of pulmonary artery compression due to fibrous mediastinitis with endovascular stent placement. Chest. 2001;119;966–968.

36. Westerly BD, Johnson GB, Maldonado F, et al. Targeting B lymphocytes in progressive fibrosing mediastinitis. Am J Resp Crit Care Med. 2014;190:1069–1071.